Medical/Pharmaceuticals
Lunit Expands Presence in Europe: to Deliver AI-powered Cancer Screening Solution to France and Portugal
* New supply contract to bring Lunit INSIGHT CXR to TeleDiag in France and Lunit INSIGHT MMG to the Central region branch of the Portuguese League Against Cancer SEOUL, South Korea, March 18, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diag...
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time
* Revenue Up 2.5% Year-over-Year to RMB40,341 Million; Excluding COVID-19 Commercial Projects, Up 25.6% * Net Profit Attributable to the Owners of the Company[1] Increased 9.0% to RMB9,607 Million; Diluted Earnings per Share (EPS) Increased 14.9% to RMB3.24 * Adjusted Non-IFRS Net Profit Att...
Aquedeon Medical Announces First Patient Enrolled in the IDE Study of Duett(TM) Vascular Graft System
SUNNYVALE, Calif., March 18, 2024 /PRNewswire/ -- Aquedeon Medical, Inc., a Silicon Valley pioneering medical device company specializing in novel cardiothoracic solutions, is pleased to announce a significant milestone with initiation of its investigational device exemption (IDE) clinical tri...
Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis
SHENZHEN, China, March 18, 2024 /PRNewswire/ -- On March 18 2024, Shenzhen chipscreen biosciences Co., Ltd. (hereinafter referred to as "chipscreen biosciences", stock code: 688321. SH) announced that the Phase II clinical trial (CGZ203 study) of chiglitazar monotherapy for non-alcoholic steatoh...
KeChow Pharma Announces NMPA Approval of Tunlametinib (HL-085) as the First Targeted Therapy for Patients with NRAS Mutated Advanced Melanoma and Previously Treated with PD-1/PD-L1
-- Tunlametinib is poised to be a potential best-in-class MEK inhibitor based on positive data from the pivotal Phase 2 study SHANGHAI, March 18, 2024 /PRNewswire/ -- KeChow Pharma, a commercial-stage pharmaceutical company focused on developing and commercializing differentiated small molecule ...
Mediwave Earns Global Recognition at GLOMO Awards 2024 for Emergency Response HealthTech
SINGAPORE, March 17, 2024 /PRNewswire/ -- Mediwave, a leading-edge HealthTech company, was recognised as a finalist at the prestigious Global Mobile Awards (GLOMO), part of the Mobile World Congress (MWC) powered by GSMA inBarcelona, Spain. This acknowledgment underscores Mediwave's exceptional c...
ImmVira's oncolytic product MVR-T3011 IT Intratumoral Injection Receives FDA Fast Track Designation for HNSCC Treatment
SHENZHEN, China, March 15, 2024 /PRNewswire/ -- ImmVira has recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for oncolytic virus product MVR-T3011 IT (intratumoral injection) for the treatment of recurrent or metastatic head and neck squamous ...
Biotheus Expanded Their Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific Antibody-Drug Conjugates
ZHUHAI, China, March 15, 2024 /PRNewswire/ -- On March 14, 2024, Biotheus Inc. (Biotheus), a clinical-stage biotech company focusing on the discovery and development of biologics for oncology and inflammatory diseases, and Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma,03692.HK), China's le...
I-Mab Reports Full Year 2023 Financial Results and Business Update
* Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end ofMarch 2024 * Uliledlimab (CD73 antibody) on track to file an IND in combination with chemotherapy and checkpoint inh...
D3 Bio Appoints Dr. Antoine Yver as Independent Board Member
SHANGHAI, March 14, 2024 /PRNewswire/ -- D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs, welcomesAntoine Yver, MD. ,MSc. as the new independent board member, effectiveMarch 4, 2024. Dr. Yver has 34 years of e...
Lunit SCOPE AI Enhances Pathologist Concordance and Accuracy in HER2, ER, and PR Assessment - New Study in Breast Cancer Research
- Lunit SCOPE HER2 and Lunit SCOPE ER/PR significantly improve pathologist concordance and accuracy, paving the way for improved breast cancer molecular subtype analysis for informed decision-making and precision patient care SEOUL, South Korea, March 14, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ...
Study of Kintor's c-Myc Degrader Published in Subsidiary Journal of Nature
SUZHOU, China, March 14, 2024 /PRNewswire/ -- Kintor Pharmaceutical Limited (" Kintor Pharma", HKEX: 9939.HK), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announces that Kintor and its cooperative partner had published an article namedMY...
Pulsenmore is expanding the application of its home ultrasound solution for pregnant women: a clinical trial with Michigan Medicine will focus on the remote assessment of the fetal biophysical profile
RAMAT GAN, Israel, March 13, 2024 /PRNewswire/ -- Pulsenmore (TASE:PULS), the world leader in self-scan ultrasound technology for at-home use and remote clinical diagnosis, announces its new clinical study collaboration with Michigan Medicine. The study will examine the ability to conduct a remot...
Update on Lunit's Acquisition of Volpara: New Zealand High Court Initial Approval Secured
- Volpara shareholder meeting to be held on April 12, 2024: Culminating the acquisition journey for Lunit, finalization set for May SEOUL, South Korea, March 13, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today ...
YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024
SHANGHAI, March 13, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech
company pioneering inin vivo gene editing therapies, today announced
participation in TIDES Asia 2024, March 19th to 21st, 2024, at the Westin
Miyako Kyoto inKyoto, Japan.
TIDES Asia
Sanyou Biopharmaceuticals Launches Advanced Intelligent R&D Service Platform
SHANGHAI, March 12, 2024 /PRNewswire/ -- Sanyou Biopharmaceutical Co., Ltd. is delighted to announce the official launch of the "Sanyou Intelligent Innovative Biologics R&D Service Platform," representing a transformative advancement in biopharmaceutical research and development. Our platform en...
AITRICS to Participate in HIMSS USA 2024
- Three consecutive years of participation in HIMSS USA - Showcasing 'VitalCare' which is an AI Solution for Predicting Patient Deterioration. SEOUL, South Korea, March 12, 2024 /PRNewswire/ -- AITRICS (CEO Kwang joon Kim), a company specializing in medical artificial intelligence (AI) technology...
Datasea to Drive Growth in its Acoustic Business via Product Upgrades and U.S. Market Entry
BEIJING, March 12, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative business segments for Acoustics Hi-tech and 5G-AI multimodal communication technology inChina and the U.S., announced today its latest plan for the Company's...
Mabwell to Present Pre-clinical Results at the 2024 American Association for Cancer Research (AACR) Annual Meeting
SHANGHAI, March 12, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present results of three preclinical studies as poster presentation at the AACR Annual Meeting to be held inSan Diego, USA, from April 5...
Zhongchao Inc. Announces Successful Medication Assistance Services for Over 7,000 SLE Patients with Approximately 130,000 Units of Medications
SHANGHAI, March 12, 2024 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that Shanghai Zhongxin Medical Technology Co., Ltd. ("Zhongxin")...
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 291 media titles]
2024-04-30 10:11Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 249 media titles]
2024-04-30 15:13New International Land-Sea Trade Corridor achieves rapid development
[Picked up by 246 media titles]
2024-04-28 10:24